Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2018

Filing Date
Filed February 28, 2019
Period End
December 31, 2018
Security
IEX
One revenue dollarkept$0.17
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 28, 2019. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation (IEX) reported 2018 net sales of $2.48 billiona, up 9% from $2.29 billion in 2017, with an 8% increase in organic sales and a 1% favorable impact from foreign currency translation.

Operating income rose 13% to $569.1 millionb and operating margin reached 22.9%, up 90 basis points. Net income increased 22% to $410.6 million, and diluted EPS was $5.29, up $0.93 from $4.36. Excluding restructuring expense in 2018 and the 2017 gain on the sale of a business and restructuring costs, adjusted operating income was $581.2 million (up 16%), adjusted net income was $419.6 million (up 26%), and adjusted EPS was $5.41.

The company operates three reportable segments: Fluid & Metering Technologies (38% of 2018 sales), Health & Science Technologies (36%), and Fire & Safety/Diversified Products (26%). Across its 13 platforms, approximately 51% of 2018 sales were to customers outside the U.S. Cash flow from operations was $479.3 millionc, cash and equivalents totaled $466.4 million, and total borrowings were $851.1 million. The company repurchased 1.3 million shares for $173.9 million in 2018, and $377.0 million remained under its repurchase authorization at year end.

For 2019, management projected 4 to 5 percent organic revenue growth and full-year EPS in the range of $5.60 to $5.80d. The filing notes risks including trade tensions and tariffs, foreign currency movements, acquisition integration, and a goodwill and intangible asset base of $1,698.0 million and $383.3 million, respectively, at December 31, 2018.

Key Highlights

  1. Net sales of $2.48 billion in 2018, up 9%, driven by an 8% increase in organic sales and a 1% favorable currency impact.
  2. Operating income of $569.1 million, up 13%; operating margin of 22.9%, up 90 basis points.
  3. Net income of $410.6 million, up 22%; diluted EPS of $5.29, up $0.93 from $4.36 in 2017.
  4. Adjusted EPS of $5.41, up 26% from prior-year adjusted EPS of $4.31, excluding restructuring and divestiture gains/losses.
  5. Cash flows from operations of $479.3 million; cash and equivalents of $466.4 million at year end.
  6. Share repurchases of $173.9 million in 2018, with $377.0 million of authorization remaining at December 31, 2018.
  7. 2019 guidance of 4 to 5 percent organic revenue growth and full-year EPS of $5.60 to $5.80.

Follow one dollar

Of each $1.00 of revenue in FY2018, Idex kept $0.17.

  1. Revenue$2.48B100.0%
  2. Cost of revenue−$1.37B55.0%
  3. Gross profit$1.12B45.0%
  4. Operating costs−$548.8M22.1%
  5. Operating income$569.1M22.9%
  6. Interest, other & tax−$158.5M6.4%
  7. Net income$410.6M16.5%
Computed from 10-KFY2018filed February 28, 2019Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2018 revenue went

$2.48B
  • Cost of revenue: $1.37B, 55% of revenue
  • SG&A: $536.7M, 22% of revenue
  • Net income: $410.6M, 17% of revenue
  • R&D: $48.0M, 1.9% of revenue
  • Interest, other & tax: $158.5M, 6.4% of revenue

Kept 17% as net income

Full revenue history →

Financial Statements

FY2018 against FY2017

Line itemFY2018FY2017Change
Revenue$2.48B$2.29B+8.6%
Cost of Revenue$1.37B$1.26B+8.3%
Gross Profit$1.12B$1.03B+8.9%
R&D Expenses$48.00M$42.40M+13.2%
SG&A Expenses$536.72M$524.94M+2.2%
Operating Income$569.09M$502.56M+13.2%
Interest Expense$44.13M$44.89M−1.7%
Net Income$410.57M$337.26M+21.7%
EPS (Basic)$5.36$4.41+21.5%
EPS (Diluted)$5.29$4.36+21.3%
Shares Outstanding (Basic)76.41M76.23M+0.2%
Shares Outstanding (Diluted)77.56M77.33M+0.3%

Frequently Asked Questions

  1. What drove IDEX's 2018 revenue and profit growth?

    Sales rose 9% to $2.48 billion, with organic sales up 8% and a 1% favorable currency effect. The filing attributes the gross margin increase primarily to productivity initiatives and volume leverage, and operating income growth mainly to volume leverage, partially offset by higher restructuring costs in 2018.

  2. How much of IDEX's business is outside the United States?

    Approximately 51% of 2018 total sales were to customers outside the U.S., compared with 49% in 2017. Sales outside the U.S. were approximately 43% of Fluid & Metering Technologies, 56% of Health & Science Technologies, and 53% of Fire & Safety/Diversified Products segment sales in 2018.

  3. What is IDEX's outlook for 2019?

    Management projected 4 to 5 percent organic revenue growth in 2019 and full-year 2019 EPS in the range of $5.60 to $5.80, while acknowledging that trade tensions and geopolitical uncertainty persist.

  4. How is IDEX's balance sheet and debt position?

    Total borrowings were $851.1 million at December 31, 2018, with no balance outstanding under the $700.0 million Revolving Facility and $8.8 million of letters of credit, leaving net available capacity of $691.2 million. The company reported it was in compliance with its covenants, with an interest coverage ratio of 15.65 to 1 and a leverage ratio of 1.27 to 1.

  5. What are the main risks highlighted in the filing?

    Key risks include economic conditions in the U.S. and abroad, international operations and currency fluctuations, trade policy and tariffs, the ability to make and integrate acquisitions, competition, and the risk of goodwill and intangible asset write-offs given goodwill and intangibles of $1,698.0 million and $383.3 million, respectively.